APP gains drug approval

Schaumburg-based APP Pharmaceuticals Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc., announced that it received approval from the U.S. Food and Drug Administration to market Indomethacin for injection.

APP will supply Indomethacin 1 mg as single dose vials. APP's Indomethacin is bar-coded, preservative-free and latex-free. According to IMS data, 2009 sales of this product in the United States were approximately $22.5 million.

The drug is used in neonates to treat patent ductus arteriosus, a common congenital heart defect.